|Bid||49.00 x 1000|
|Ask||54.87 x 800|
|Day's Range||51.81 - 53.88|
|52 Week Range||27.53 - 54.37|
|Beta (5Y Monthly)||1.91|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 25, 2020 - Mar 06, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||60.00|
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced positive topline results from part 2 of FIREFISH demonstrating that the study met its primary endpoint of proportion of infants who are sitting without support after 12 months of treatment. The pivotal study assessed the efficacy of risdiplam (RG7916) in infants with type 1 spinal muscular atrophy (SMA), the most severe, infantile onset form of this rare and devastating neuromuscular disease. Risdiplam has been well tolerated and no treatment-related safety findings leading to withdrawal have been observed in any risdiplam trial to date. Data from part 2 of the FIREFISH study will be shared with health authorities globally and will be presented at an upcoming medical congress.
PTC Therapeutics, Inc. (NASDAQ: PTCT) today is providing a corporate update that will be presented at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th at 8:30 a.m. PST. Stuart W. Peltz, Ph.D., PTC's Chief Executive Officer, will provide an update on the 2019 accomplishments and highlight value creating events in the upcoming year. Additionally, the Company is providing preliminary 2019 financial results and 2020 financial guidance. The presentation will be webcast live on the Events and Presentations page under the investors' section of PTC Therapeutics' website at www.ptcbio.com
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th at 8:30 a.m. PST.
We are still in an overall bull market and many stocks that smart money investors were piling into surged in 2019. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained more than 57% each. Hedge funds' top 3 stock picks returned 44.6% this year and beat the S&P 500 […]
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on December 9, 2019 it approved non-statutory stock options to purchase an aggregate of 59,150 shares of its common stock to 17 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation.
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...
The FDA accepts Roche's (RHHBY) NDA for risdiplam under a priority review to treat spinal muscular atrophy. A verdict is pending on May 24, 2020.
It has been a record-breaking year for the stock market, with new highs repeatedly being reached. The S&P 500 has broken its all-time-record 19 times this year, overall making 25% gains. Traditionally, or more accurately, 71% of the time, when the S&P 500 has recorded such annual gains, the rally continues the following year.According to leading investment bank Credit Suisse, next year won’t be an anomaly. The Swiss institution’s chief U.S. equity strategist Jonathan Golub says healthier revenue growth, reduced profit headwinds, and a reversal of slowing economic data are among reasons why the market could gain another 10% by the end of 2020.Not ones to argue with such experts, as Credit Suisse ranks 5th in TipRanks’ Top Performing Research Firms, we thought we’d take a look at some stocks the financial giant currently has on its radar, specifically ones with a Strong Buy consensus rating. Let’s take a look.Lyft (LYFT)First on our list is Lyft, which has been left on the curb waiting for some good news to arrive. Since going public in March, the ridesharing company has had a torrid time in the market, on a downward spiral whilst shedding over 40% of its value. But is the gloom finally about to - there’s no other way of putting this - lyft?Since the start of October it has added 11% to its share price, indicating next quarter’s report might be the first to note positive gains. The recent boost in the market can be attributed to former rival Juno, which closed shop in New York and saw its corporate clients picked up by Lyft. Credit Suisse’s Stephen Ju recently hosted an investor meeting with several leading members from the Lyft team, and he is confident the company is taking the right steps towards profitability. The 5-star analyst reiterated his Buy rating along with a price target of $96. His target implies a grand increase of 106% should the target be reached. (To watch Ju’s track record, click here)Among key takeaways for Ju were Lyft’s easing on promotional campaigns, as its marketing and promotional spend has put downward pressure on profitability, improved data on consumer behavior which will help improve the Lyft product and the onboarding of external insurance providers which should have the ability to drive contribution profit. Ju concluded, “Lyft is more focused on adding higher value users and rides. And with the recent price hikes and the ongoing reduction of contra revenue incentives, the company places greater emphasis on revenue share gain.” Sharing the positivity, with 19 Buys and 6 Holds assigned in the last three months, the Street is in the same lane as Ju, giving Lyft a Strong Buy consensus. The average price target is $68.82, implying handsome upside of 48% from its current price of $46.35. (See Lyft stock analysis on TipRanks)PTC Therapeutics (PTCT)PTC Therapeutics develops orally administered drugs for what are known as orphan diseases – disorders so rare that their lack of a market makes it hard to receive funding for the purpose of developing treatments.The company has several approved medicines worldwide and several more in the pipeline. Currently the spotlight is on its Risdiplam drug, in advanced development for the treatment of spinal muscular atrophy (SMA).The company recently reported positive SUNFISH (type 2/3 SMA) Part 2 Ph3 results for the drug which left management extremely pleased with the outcome. The SUNFISH trial is a two-part study evaluating Risdiplam in people with Type 2 and 3 SMA between 2 and 25 years of age. The data is set to be presented in February at the SMA conference in France.Credit Suisse’s Martin Auster recently met with PTCT management, and the analyst came away impressed, noting, “We are incrementally more confident that PTCT is well positioned over the next year with multiple catalysts on the horizon, most importantly announcement of Risdiplam NDA submission Q4 2019,” further adding, “We see Risdiplam being standard of care for older type 2/3 SMA patients, with the opportunity to achieve ~$3b in global sales (PTC is eligible for tiered high single digit to low double digit royalties.”Auster’s confidence in PTC has caused him to increase his price target to $58, implying an ample 36% increase from the biotech’s current price. (To watch’s Auster’s track record, click here)The analyst’s bullishness gets the backing of his colleagues, as the rising biotech currently has a Strong Buy rating from the Street. The 5 "buys" and 1 "hold" ratings provide an average price target of $59.50, implying upside of 39% from its current price of $42.71. (See PTCT stock analysis on TipRanks)SunPower (SPWR)Possibly named following a very short brainstorming session, SunPower is an energy company which designs and manufactures solar panels.At least that was simple. Things have recently gotten a little more complicated, after the company spun off part of its business to create a new company called, Maxeon Solar. The new company will manufacture solar cells overseas, while SunPower will cater to the residential and commercial solar markets in the US. Apart from hoping the move will provide a boost to SunPower shares, Chief Executive Officer Thomas Werner said, “This transaction will also simplify both organizational structures, lowering costs, while improving efficiency and creating (two) more nimble companies.”SunPower’s stock has had quite a ride this year, increasing by 200% before crashing back down whilst shedding 50% of its value. Credit Suisse’s Michael Weinstein thinks the pullback could be the right time for investors to hop onboard. The analyst said, “We reiterate our Outperform rating given continued focus on US distributed generation (DG) business, company shores up much awaited manufacturing partner (TZS’ $298m investment and capacity expansion plan), addresses overhangs (legacy liabilities and convertible debt refinance), and unlocks sum of parts (Maxeon Solar to be listed by 2Q20).” Weinstein’s price target is $14.50, indicating substantial gains of 102%. (To watch’s Weinstein’s track record, click here)The analyst is in good company, as the rest of the Street currently rates SPWR a Strong Buy. Over the last 3 months, 3 analysts have recommended a Buy on SPWR and 1 suggests a Hold. With an average stock-price forecast of $13.88, resulting in gains of 95%. (See SunPower stock analysis on TipRanks)
SOUTH PLAINFIELD, N.J. , Nov. 19, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will participate in a panel discussion titled, "Gene Therapy with Base ...
SOUTH PLAINFIELD, N.J., Nov. 18, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced the launch of a no-cost testing program for aromatic L-amino acid decarboxylase (AADC) deficiency, a rare genetic condition. Children with AADC deficiency fail to thrive and commonly don't reach developmental milestones that include being able to hold up their head, sit unassisted, and stand.1 These patients also have muscular hypotonia, severe seizure-like episodes that include oculogyric crises, and the need for intensive life-long care.1 To raise awareness and identify misdiagnosed AADC deficiency patients, PTC has launched a no-cost testing program to genetically distinguish these patients from those with other disorders.
SOUTH PLAINFIELD, N.J., Nov. 11, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced positive results from part 2 of SUNFISH demonstrating that the study met its primary endpoint of change from baseline after 1 year of treatment with risdiplam compared to placebo as measured by the Motor Function Measure 32, a scale monitoring severity and progression of fine and gross motor function in patients with a neuromuscular disease such as spinal muscular atrophy (SMA). Data from part 2 of the SUNFISH study will be presented at an upcoming medical congress. "We are very pleased with the results of the SUNFISH study and are excited to move one step closer to bringing risdiplam globally to all patients living with SMA.
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of 2.20% and 5.78%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Tegsedi® approved in Brazil & PTC is prepared for launch PTC completed financing with net proceeds of approximately $376 million SOUTH PLAINFIELD, N.J. , Oct. 29, 2019 /PRNewswire/ -- PTC Therapeutics, ...
PTC Therapeutics, Inc.'s (NASDAQ:PTCT): PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery...
SOUTH PLAINFIELD, N.J., Oct. 24, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced new results from its investigational gene therapy, PTC-AADC, in patients living with aromatic L-amino acid decarboxylase (AADC) deficiency. The data were presented at the Child Neurology Society 48th Annual Meeting. "We are excited to see the transformational effects in AADC deficiency patients in this long-term study as patients with severe AADC deficiency never achieve the ability to sit, walk or talk," said Stuart Peltz, Ph.D., Chief Executive Officer of PTC Therapeutics.
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P […]